% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tichanek:282681,
      author       = {F. Tichanek and A. Försti$^*$ and V. Liska and O. Hemminki
                      and A. Koskinen and A. Hemminki and K. Hemminki$^*$},
      title        = {{E}arly mortality critically impedes improvements in
                      thyroid cancer survival through a half century.},
      journal      = {European journal of endocrinology},
      volume       = {189},
      number       = {3},
      issn         = {0001-5598},
      address      = {Bristol},
      publisher    = {BioScientifica Ltd.},
      reportid     = {DKFZ-2023-01827},
      pages        = {355 - 362},
      year         = {2023},
      note         = {#LA:C020#},
      abstract     = {We analyze survival in thyroid cancer from Denmark (DK),
                      Finland (FI), Norway (NO), and Sweden (SE) over a 50-year
                      period (1971-2020), and additionally consider concomitant
                      changes in incidence and mortality.Population-based survival
                      study.Relative 1-, 5/1 (conditional)-, and 5-year survival
                      data were obtained from the NORDCAN database for years
                      1971-2020. Incidence and mortality rates were also
                      assessed.A novel consistent observation was that 1-year
                      survival was worse than 5/1-year survival but the difference
                      between these decreased with time. Relative 1-year survival
                      in thyroid cancer (mean for the 4 countries) reached
                      $92.7\%$ for men and $95.6\%$ for women; 5-year survival
                      reached $88.0\%$ for men and $93.7\%$ for women. Survival
                      increased most for DK which started at a low level and
                      reached the best survival at the end. Male and female
                      incidence rates for thyroid cancer increased 3- and 4-fold,
                      respectively. In the same time, mortality halved for men and
                      for women, it decreased by 2/3.We documented worse relative
                      survival in the first year than in the 4 subsequent years,
                      most likely because of rare anaplastic cancer. Overall
                      survival in thyroid cancer patients increased in the Nordic
                      countries in the course of 50 years; 5-year survival was
                      close to $90\%$ for men and close to $95\%$ for women. Even
                      though overdiagnosis may explain some of 5-year survival
                      increase, it is unlikely to influence the substantial
                      increase in 1-year survival. The unmet need is to increase
                      1-year survival by diagnosing and treating aggressive tumors
                      before metastatic spread.},
      keywords     = {Female / Humans / Male / Thyroid Neoplasms: diagnosis /
                      Thyroid Neoplasms: epidemiology / Databases, Factual /
                      Finland: epidemiology / Norway: epidemiology / anaplastic
                      cancer (Other) / diagnostics (Other) / relative survival
                      (Other) / treatment (Other)},
      cin          = {B062 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37675794},
      doi          = {10.1093/ejendo/lvad117},
      url          = {https://inrepo02.dkfz.de/record/282681},
}